Want to see BLGO full AI Analyst Report?
Top Page
BioLargo
(OTC:BLGO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.09
▼(-7.00% Downside)
Action:Reiterated
Date:09/15/26
BLGO’s score is primarily held back by very weak financial performance (revenue contraction, outsized losses, negative equity, and significant cash burn). Technicals also remain unfavorable with the stock below major moving averages and negative MACD. The earnings call adds some support due to ambitious commercialization plans and partnership progress, but execution, timing, and financing risks remain prominent; valuation metrics provide limited support given negative earnings.
Positive Factors
Core engineering growth and self-sufficiency
Growth in third-party engineering sales provides a recurring foundation beyond individual product launches. Management also described the engineering business as essentially self-sufficient and profitable excluding BioLargo-funded R&D, supporting more durable operating economics.
Negative Factors
Revenue contraction and severe operating losses
The revenue decline reverses prior growth and leaves the current business base far too small relative to operating costs. Extremely negative operating and net margins indicate that commercialization has not yet produced sustainable operating leverage, increasing the need for external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Core engineering growth and self-sufficiency
Growth in third-party engineering sales provides a recurring foundation beyond individual product launches. Management also described the engineering business as essentially self-sufficient and profitable excluding BioLargo-funded R&D, supporting more durable operating economics.
Read all positive factors
BioLargo (BLGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$30.00M
Dividend YieldN/A
Average Volume (3M)406.74K
Price to Earnings (P/E)―
Beta (1Y)-0.19
Revenue Growth-70.95%
EPS Growth-257.36%
CountryUS
Employees45
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.05
Shares Outstanding328,731,350
10 Day Avg. Volume419,764
30 Day Avg. Volume406,742
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$5.28M
BioLargo Business Overview & Revenue Model
Company Description
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contaminat...
How the Company Makes Money
BioLargo generates revenue primarily through a combination of (1) product and technology commercialization and (2) service/engineering activities tied to environmental solutions. Product-driven revenue can include sales of odor/VOC control product...
BioLargo Earnings Call Summary
Earnings Call Date:Aug 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call was strongly forward-looking and optimistic, emphasizing revenue growth in the core engineering business, multiple distribution channels for Clyra, PFAS commercial progress, new ventures, and potential contract opportunities. However, management also acknowledged a difficult year marked by a market capitalization decline of more than 60%, the loss of the Pooph business, a close to $4 million write-down, Clyra’s launch delay and burn rate, and ongoing financing and regulatory uncertainty. The number and strength of the stated achievements and initiatives outweighed the stated challenges.Positive Updates
Core Engineering Business Revenue Growth
Quarter-to-quarter revenue increased, with growth driven by the engineering group’s increased sales to third-party customers. The remainder of the products and services provided by ONM also increased, and management described the core business as growing and stable.
Negative Updates
Market Capitalization Decline
Management stated that BioLargo’s market capitalization declined by well over 60%, approaching 70%, during the prior year.
Read all updates
Q2-2026 Updates
Positive
Negative
Core Engineering Business Revenue Growth
Quarter-to-quarter revenue increased, with growth driven by the engineering group’s increased sales to third-party customers. The remainder of the products and services provided by ONM also increased, and management described the core business as growing and stable.
Read all positive updates
Company Guidance
Management expects to launch the consumer products category in the October time frame, with a conservative target of about half the numbers that Pooph generated, realistically coming in the $15-plus million range over the first course of a year to 1.5 years; Clyra’s national distribution launch is targeted for 2027 start, with a 3- to 6-month setup, while its 3 active distributors encompass probably 70-plus percent of the market. Cellinity’s strategy involves factories with about $250 million of CapEx, factories of about $170 million each, incentives as much as 50% of CapEx, and a Puerto Rico project where 80-plus percent of the project can get financed with incentives; its design targets 10 years, no degradation and another 10-year cycle with only 4% degradation, versus a 7-year market with up to 15% degradation. The minerals facility is expected to move to Phase 2, probably somewhere around the $10 million range, take about a year, 1.5 years, and potentially lead to a design build probably something in the $40 million range; water projects being scoped include $5 million, $10 million, $25 million and $30 million projects, including systems of 3 million gallons a day, with a proposed 80% reduction in OpEx. A multimillion-dollar military grant is hoped to get funded in Q1, and the annual meeting target is December 1.BioLargo Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.08M | 7.76M | 17.78M | 12.23M | 5.88M | 2.53M |
| Gross Profit | 1.63M | 3.41M | 7.85M | 6.15M | 2.86M | 1.10M |
| EBITDA | -17.74M | -14.55M | -4.06M | -4.19M | -5.10M | -6.70M |
| Net Income | -14.48M | -11.78M | -2.40M | -3.50M | -4.50M | -7.38M |
Balance Sheet | ||||||
| Total Assets | 6.67M | 8.31M | 10.51M | 8.21M | 4.86M | 3.02M |
| Cash, Cash Equivalents and Short-Term Investments | 2.19M | 3.88M | 3.55M | 3.54M | 1.85M | 962.00K |
| Total Debt | 6.39M | 3.51M | 2.55M | 1.70M | 1.47M | 1.13M |
| Total Liabilities | 9.40M | 6.79M | 4.46M | 4.00M | 2.85M | 2.09M |
| Stockholders Equity | -1.85M | 4.04M | 8.85M | 6.84M | 4.88M | 4.65M |
Cash Flow | ||||||
| Free Cash Flow | -10.37M | -8.34M | -4.44M | -2.84M | -3.03M | -3.97M |
| Operating Cash Flow | -10.32M | -8.30M | -3.21M | -2.37M | -2.76M | -3.94M |
| Investing Cash Flow | 51.00K | 435.00K | -1.32M | -478.00K | -271.00K | -34.00K |
| Financing Cash Flow | 8.99M | 8.22M | 4.44M | 4.66M | 3.96M | 4.23M |
BioLargo Technical Analysis
Negative
0.10
Price Trends
0.10
Negative
0.12
Negative
0.14
Negative
Market Momentum
>-0.01
Positive
41.68
Neutral
21.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.68 is Neutral, neither overbought nor oversold. The STOCH value of 21.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.
BioLargo Risk Analysis
BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLargo Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | $243.88M | -7.94 | -19.75% | 2.52% | -7.63% | -15.10% | |
52 Neutral | $564.15M | -4.01 | -52.28% | 4.12% | -3.56% | 68.49% | |
47 Neutral | $437.69M | -24.56 | -2.20% | 3.95% | 2.96% | -122.83% | |
46 Neutral | $672.34M | -1.22 | -40.45% | 4.75% | 3.53% | -118.53% | |
44 Neutral | $30.00M | -2.02 | -548.88% | ― | -70.95% | -257.36% |
* Basic Materials Sector Average
BLGO
BioLargo
0.09
-0.11
-54.04%
FF
Futurefuel
5.56
1.77
46.66%
TROX
TRONOX
4.21
-0.38
-8.36%
RYAM
Rayonier Advanced Materials
8.34
1.34
19.14%
ASIX
AdvanSix
16.21
-3.04
-15.78%
BioLargo Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
BioLargo Highlights Investor Presentation and Disclosure Practices
Neutral
Sep 11, 2026
On September 10, 2026, BioLargo, Inc. presented a slide deck at a webcast investor conference, and subsequently furnished those materials to the U.S. Securities and Exchange Commission in a Current Report on Form 8-K. The company emphasized that t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.